With the number of influenza cases rising for the longest period ever after the COVID-19 endemic, Xofluza is expected to open a new paradigm in post-exposure prophylaxis treatment.

On the 17th, HK Inno.N announced that it had signed an exclusive distribution and joint sales agreement with Roche Korea for Roche’s ‘Xofluza (baloxavir marboxil) in Korea.

HK Inno.N will be in charge of distributing Xofluza for 2 years and will be jointly market and sell the drug with Roche Korea.

Xofluza was the first new influenza treatment developed in 20 years. The drug rapidly reduces flu symptoms compared to placebo with a single oral dose and reduces the detection of influenza virus. <